Moderna (NASDAQ:MRNA) Coverage Initiated by Analysts at Sanford C. Bernstein

Stock analysts at Sanford C. Bernstein initiated coverage on shares of Moderna (NASDAQ:MRNA) in a report released on Thursday, Briefing.com reports. The brokerage set a “market perform” rating and a $55.00 price target on the stock. Sanford C. Bernstein’s price objective suggests a potential downside of 4.28% from the stock’s current price.

Several other research firms have also recently weighed in on MRNA. William Blair reiterated a “market perform” rating on shares of Moderna in a research report on Thursday, June 27th. Bank of America lowered their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. HSBC upgraded Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price objective on the stock in a research report on Wednesday, August 28th. The Goldman Sachs Group lowered their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Finally, Jefferies Financial Group lowered their price objective on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research report on Tuesday. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $97.18.

Moderna Trading Up 0.3 %

NASDAQ MRNA opened at $57.46 on Thursday. The stock has a 50 day moving average of $71.95 and a 200-day moving average of $105.27. Moderna has a 12 month low of $55.70 and a 12 month high of $170.47. The company has a market cap of $22.02 billion, a PE ratio of -3.67 and a beta of 1.66. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to the consensus estimate of $128.41 million. During the same quarter last year, the firm posted ($3.62) EPS. The company’s quarterly revenue was down 29.9% on a year-over-year basis. On average, equities research analysts anticipate that Moderna will post -9.85 EPS for the current fiscal year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $117.80, for a total value of $1,767,000.00. Following the sale, the director now directly owns 2,239,015 shares in the company, valued at $263,755,967. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 24th. The shares were sold at an average price of $117.80, for a total value of $1,767,000.00. Following the completion of the transaction, the director now directly owns 2,239,015 shares in the company, valued at approximately $263,755,967. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,184 shares of company stock worth $3,804,931 over the last ninety days. Insiders own 15.70% of the company’s stock.

Institutional Investors Weigh In On Moderna

A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. Fisher Asset Management LLC purchased a new stake in Moderna in the 4th quarter valued at $206,000. HighPoint Advisor Group LLC bought a new position in shares of Moderna during the 4th quarter worth $491,000. Los Angeles Capital Management LLC bought a new position in shares of Moderna during the 1st quarter worth $2,693,000. GAMMA Investing LLC grew its stake in shares of Moderna by 37.8% during the 1st quarter. GAMMA Investing LLC now owns 2,994 shares of the company’s stock worth $319,000 after acquiring an additional 822 shares during the period. Finally, Mather Group LLC. bought a new position in Moderna in the 1st quarter worth about $57,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.